Minerva Neurosciences Presents Pre-Clinical Data Suggesting a Mechanistic Role of Roluperidone in Addressing Negative Symptoms of Schizophrenia
11. April 2019 08:30 ET
|
Minerva Neurosciences, Inc
Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM,...
Journal of Clinical Psychiatry Publishes Positive Results of Cognitive Performance From Phase 2B Trial of Roluperidone, Under Development by Minerva Neurosciences for the Treatment of Negative Symptoms in Schizophrenia
17. Mai 2018 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports First Quarter 2018 Financial Results and Business Updates
03. Mai 2018 07:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences to Report Fiscal 2017 Fourth Quarter and Year End Financial Results and Business Updates on March 12, 2018
05. März 2018 08:30 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Screens First Patient in Phase 3 Trial Of MIN-101 to Treat Negative Symptoms in Schizophrenia
19. Dezember 2017 08:00 ET
|
Minerva Neurosciences, Inc
Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM,...
Minerva Neurosciences Reports Second Quarter 2017 Financial Results and Business Updates
03. August 2017 07:30 ET
|
Minerva Neurosciences, Inc.
FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half...
American Journal of Psychiatry Publishes Minerva Neurosciences’ MIN-101 Phase 2b Trial Results for Treatment of Negative Symptoms in Schizophrenia
31. Juli 2017 08:30 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Announces Outcome of End-of-Phase 2 Meeting With FDA
15. Mai 2017 08:00 ET
|
Minerva Neurosciences, Inc.
Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3...
Minerva Neurosciences Reports First Quarter 2017 Financial Results and Business Updates
04. Mai 2017 07:45 ET
|
Minerva Neurosciences, Inc.
WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Reports Fiscal 2016 Fourth Quarter and Year End Financial Results and Business Updates
13. März 2017 07:30 ET
|
Minerva Neurosciences, Inc.
Multiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017 Management to host conference call today at...